# Evidence Quality Assessment Report
## 15 Competency Questions - 2026-02-01 Validation Round

**Assessment Date**: 2026-02-01
**Assessor Role**: Evidence Quality Assessor Agent
**Total CQs Evaluated**: 15
**Assessment Status**: COMPLETE âœ…

---

## Quick Summary

This assessment evaluates the **quality and completeness of evidence** in all 15 competency question (CQ) summaries from the 2026-02-01 validation round.

### Key Findings
- **93.3%** of CQs achieve MEDIUM or HIGH quality rating (14 of 15)
- **7.3 CURIEs** average per CQ (110 total identifiers)
- **5.3 API tools** average per CQ (diverse data sources)
- **1.8 confidence scores** average per CQ (47% have quantified metrics)

### Quality Distribution
- **HIGH**: 7 CQs (46.7%) - Excellent evidence, multiple validation sources
- **MEDIUM**: 7 CQs (46.7%) - Adequate evidence, some gaps
- **LOW**: 1 CQ (6.7%) - CQ-12 requires remediation

---

## Report Files

### 1. ASSESSMENT_SUMMARY.md (8.7 KB) - START HERE
**Executive overview with visual tables and quick insights**
- Key metrics and quality scorecard
- API tool distribution and usage patterns
- CURIE type breakdown (HGNC, ChEMBL, NCT, etc.)
- Confidence score analysis by CQ type
- Exemplary vs. problematic evidence patterns
- Actionable recommendations (urgent, short-term, medium-term)
- Overall assessment and final verdict

**Best for**: Quick reference, presentations, stakeholder updates

---

### 2. EVIDENCE_QUALITY_REPORT.md (16 KB) - DETAILED ANALYSIS
**Comprehensive technical report with detailed findings**
- Detailed quality assessment for each of 15 CQs
- Statistical summary and distribution analysis
- Quality assessment details (HIGH/MEDIUM/LOW rationale)
- API ecosystem analysis and contribution breakdown
- Cross-question patterns and design implications
- Provenance strength assessment for exemplary and weak CQs
- Specific remediation recommendations
- Validation gaps and remediation strategies

**Sections**:
1. Executive Summary
2. Evidence Quality Scorecard (all 15 CQs ranked)
3. Statistical Summary
4. Quality Assessment Details (by rating)
5. API Tool Analysis
6. CURIE Type Distribution
7. Provenance Strength Assessment
8. Cross-Question Patterns
9. Recommendations for Enhancement
10. Conclusion

**Best for**: Technical review, detailed understanding, improvement planning

---

### 3. evidence_quality_scorecard.csv (3.2 KB) - DATA EXPORT
**Machine-readable data for further analysis**
- All 15 CQs with quantified metrics
- CURIEs count, API tools count, confidence scores count
- Quality ratings and primary domain classification
- API tool lists and CURIE type breakdown
- Confidence score details

**Format**: CSV (comma-separated values)
**Rows**: 15 (one per CQ) + 1 header
**Columns**: 9 data columns

**Best for**: Data analysis, trend analysis, visualization, metric tracking

---

## Evidence Assessment Methodology

### Scoring Criteria

**CURIEs Resolved**: Count biological/clinical identifiers
- HGNC (genes), ChEMBL (compounds), NCT (trials)
- MONDO (diseases), WP (pathways), UniProt (proteins)
- **Expected**: 4-11 per CQ

**API Tools Used**: Count distinct APIs/endpoints invoked
- hgnc_search/get, chembl_search/get, string_search/get
- opentargets_get, wikipathways_*, curl (direct API calls)
- **Expected**: 5-7 per CQ

**Confidence Scores**: Count quantified metrics
- STRING interaction scores (0.0-1.0)
- Open Targets disease association scores
- Other numerical metrics with evidence
- **Expected**: 2-3 per CQ (if applicable)

### Quality Rating Logic

```
HIGH Quality:
  (CURIEs >= 4 AND API Tools >= 5) OR Confidence Scores >= 3

MEDIUM Quality:
  (CURIEs >= 4 AND API Tools >= 3) OR CURIEs >= 9
  AND NOT (flagged as LOW)

LOW Quality:
  Single API tool dependency OR
  CURIEs < 4 with no cross-validation
```

---

## Key Findings by Quality Tier

### ðŸŒŸ HIGH Quality CQs (7)
**Exemplary Evidence with Multiple Validation Sources**

| CQ | Title | Strength |
|----|-------|----------|
| CQ-3 | Alzheimer's Gene-Protein Network | 7 STRING scores + 11 CURIEs |
| CQ-6 | BRCA1 Regulatory Network | 6 interaction scores + 9 genes |
| CQ-1 | Palovarotene Mechanism for FOP | 7 API tools + multi-source validation |
| CQ-10 | Huntington's Disease Novel Targets | 5 STRING scores + 6 API tools |
| CQ-11 | p53-MDM2-Nutlin Axis | 3 interaction scores + 7 API tools |
| CQ-5 | MAPK Regulatory Cascade | 2 canonical scores + 8 genes |
| CQ-7 | NGLY1 Deficiency Drug Repurposing | 2 interaction scores + 7 API tools |

**Pattern**: Gene/protein-centric with STRING validation

---

### âš ï¸ MEDIUM Quality CQs (7)
**Adequate Evidence with Identifiable Gaps**

| CQ | Title | Gap |
|----|-------|-----|
| CQ-2 | FOP Drug Repurposing | 0 confidence scores (mechanism unquantified) |
| CQ-4 | Alzheimer's Therapeutics | 0 scores (10 CURIEs but no metrics) |
| CQ-8 | ARID1A Synthetic Lethality | 0 scores (synthetic lethal unquantified) |
| CQ-9 | Dasatinib Safety Profile | 0 scores (off-target effects unvalidated) |
| CQ-13 | Commercialization Phase 3 | 3 API tools (limited diversity) |
| CQ-14 | Feng Synthetic Lethality | Partial (API key required for validation) |
| CQ-15 | CAR-T Regulatory Landscape | 4 API tools (minimal tool set) |

**Pattern**: Drug repurposing and clinical trial domains lack quantified confidence

---

### âŒ LOW Quality CQ (1)
**Single-Source Dependency Requiring Remediation**

| CQ | Issue | Solution |
|----|-------|----------|
| CQ-12 | Health Emergencies Clinical Trial Landscape | Add MONDO/ChEMBL/HGNC grounding for entity context |

**Problem**: Uses only ClinicalTrials.gov API (no triangulation)
**Remediation**: Map trial conditions â†’ diseases, interventions â†’ compounds, targets â†’ genes

---

## API Ecosystem Insights

### Critical (Foundation Tier)
- **HGNC**: 86.7% coverage - Gene identifier resolution
- **ChEMBL**: 66.7% coverage - Drug/compound discovery

### Expanding (Confidence Tier)
- **STRING**: 46.7% coverage - Protein interaction quantification
- **ClinicalTrials.gov**: 40.0% coverage - Clinical trial evidence

### Underutilized
- **Open Targets**: 26.7% coverage (opportunity: disease associations)
- **WikiPathways**: 13.3% coverage (opportunity: pathway context)

### Domain Gaps
- **MONDO**: 3.6% disease formalization (major opportunity)
- **UniProt**: 1.8% protein cross-references (minor)

---

## Recommendations

### Immediate (1-2 weeks)
1. **Remediate CQ-12**: Add entity grounding
   - Map diseases â†’ MONDO
   - Map interventions â†’ ChEMBL
   - Map targets â†’ HGNC
   - Expected: 1â†’4-5 APIs, +8-10 CURIEs

### Short-Term (2-4 weeks)
2. **Enhance Drug Repurposing**: Add STRING validation to CQ-2, CQ-4, CQ-8, CQ-9
3. **Expand Disease Context**: Add Open Targets to CQ-2, CQ-4, CQ-8, CQ-9
4. **Quantify Synthetic Lethality**: Validate in CQ-8, CQ-14
   - Expected: 0â†’3-5 scores per CQ

### Medium-Term (1 month)
5. **Broaden Pathway Coverage**: Apply WikiPathways to 5 additional CQs
6. **Formalize Diseases**: Add MONDO identifiers to all disease mentions (+15-20 CURIEs)
7. **Cross-Validate**: Link pathway components to interaction data

---

## How to Use This Assessment

### For QA/Validation Teams
1. Review **ASSESSMENT_SUMMARY.md** for executive overview
2. Check **evidence_quality_scorecard.csv** for specific metrics
3. Reference **EVIDENCE_QUALITY_REPORT.md** for detailed justification

### For Developers/Scientists
1. Identify gaps in CQ-2, CQ-4, CQ-8, CQ-9 (drug repurposing)
2. Remediate CQ-12 by adding entity grounding
3. Expand API coverage per recommendations

### For Stakeholders
1. **93.3% compliance** with MEDIUM+ quality demonstrates robust evidence base
2. **Recommended improvements** focus on scoring and contextualization
3. **No fundamental data gaps** - improvements are additive, not corrective

---

## Supporting Documents

### Source Data
- **summaries/** - 15 individual CQ summary markdown files
  - cq1-summary.md through cq15-summary.md
  - Each contains: Key Entities, Findings, Provenance, Graph Summary

### Related Analysis
- **GAP-ANALYSIS.md** - Detailed gap identification by domain
- **GUIDANCE copy.md** - CQ validation guidance and methodology

---

## Assessment Metrics Reference

### CURIE Types (110 Total)
| Type | Count | % | Example |
|------|-------|---|---------|
| HGNC | 65 | 59.1% | HGNC:11998 (TP53) |
| ChEMBL | 21 | 19.1% | CHEMBL:2105648 |
| NCT | 15 | 13.6% | NCT:06463861 |
| MONDO | 4 | 3.6% | MONDO:0004975 |
| WP | 3 | 2.7% | WP:WP2760 |
| UniProt | 2 | 1.8% | UniProt:P04637 |

### API Tool Coverage
| Tool | CQs | % |
|------|-----|-----|
| hgnc_search_genes | 13 | 86.7% |
| hgnc_get_gene | 12 | 80.0% |
| chembl_search_compounds | 10 | 66.7% |
| chembl_get_compound | 10 | 66.7% |
| string_search_proteins | 7 | 46.7% |
| string_get_interactions | 7 | 46.7% |
| curl(ClinicalTrials) | 6 | 40.0% |

---

## Validation Status

### Overall Assessment
âœ… **VALID WITH RECOMMENDATIONS**

**Evidence**:
- 110 total CURIEs resolved across 15 CQs
- 5.3 API tools average (diverse data sources)
- 47% of CQs have quantified confidence metrics
- 93.3% meet MEDIUM+ quality threshold
- All recommendations are additive enhancements

**Conclusion**: The evidence base is comprehensive, well-distributed, and reproducible. Recommended improvements focus on scoring diversity and clinical contextualization, not fundamental data gaps.

---

## Document Manifest

| File | Size | Lines | Purpose |
|------|------|-------|---------|
| ASSESSMENT_SUMMARY.md | 8.7 KB | 218 | Executive overview with visual tables |
| EVIDENCE_QUALITY_REPORT.md | 16 KB | 378 | Comprehensive technical analysis |
| evidence_quality_scorecard.csv | 3.2 KB | 16 | Machine-readable data export |
| README.md | This file | - | Navigation and context guide |

---

## Quick Links

- **Start Here**: [ASSESSMENT_SUMMARY.md](ASSESSMENT_SUMMARY.md)
- **Deep Dive**: [EVIDENCE_QUALITY_REPORT.md](EVIDENCE_QUALITY_REPORT.md)
- **Data Export**: [evidence_quality_scorecard.csv](evidence_quality_scorecard.csv)

---

**Report Generated**: 2026-02-01
**Assessment Period**: Complete 15-CQ validation suite
**Assessor**: Evidence Quality Assessor Agent
**Status**: COMPLETE âœ…

